American conglomerate GE Healthcare last week filed a lawsuit against California-based life sciences company Bio-Rad Laboratories on four counts of patent infringement.
US-based Allele Biotechnology & Pharmaceuticals, a preclinical-stage biopharmaceutical company, has teamed up with a scientific e-commerce marketplace network in efforts to develop nanoantibodies for therapeutic applications.
German pharmaceutical company Boehringer Ingelheim has signed a research collaboration and licence agreement with French and Canadian biopharmaceutical business Domain Therapeutics.
The National Health Service England is set to make record-breaking savings after negotiating deals with five manufacturers of low-cost biosimilar versions of the NHS's most expensive drug.
Despite the importance of IP rights to biotech and biopharma innovation, recent decisions and new policies are weakening and reducing the scope of IP-based incentives, according to a report.
Scientists have urged policymakers to implement a regulatory framework governing the use of CRISPR technology in humans, following reports that a Chinese scientist has successfully created ‘edited’ twins.
The global CRISPR technology market is expected to reach $1.72 million in value by 2023, up from 2018’s predicted figure of $562 million, according to a report released this month.
Saul Ewing Arnstein & Lehr has strengthened its Boston office with the addition of two life sciences partners from Hamilton, Brook, Smith & Reynolds.
Genome sequencing company 10x Genomics has been accused of infringing 11 patents covering cell research and analysis tools.
While the pharmaceutical industry has welcomed the draft Withdrawal Agreement for the UK’s departure from the EU, more clarity is still needed, lawyers have told LSIPR.